Vectura provides update on GSK litigation
13th September 2019
Today Vectura announces that following the award of US$89.7m in damages to Vectura by a jury in the US District Court for the District of Delaware on 3 May 2019, presiding US District Judge Richard Andrews has ruled on the parties' post-trial motions:
- Award of US$89.7m in damages to Vectura on May 3, 2019 upheld
- Ongoing royalties of 3% on US sales of certain infringing GSK Ellipta products
- Supplemental damages based on GSK's infringing sales of approximately US$10.5m
- Pre-judgment interest at the prime rate of approximately US$6.7m
Paul Fry, Vectura's Chief Financial Officer and Interim Chief Executive Officer of Vectura, said: "The judge's post-motions ruling further validates Vectura's original decision to pursue this action with GSK. We will always take action to protect and defend our intellectual property and we will provide further updates on this matter in due course."
For the full RNS update, please click here.